Evidence & innovation
The research and patents behind IrisVision
IrisVision is grounded in real science: independent, peer-reviewed studies — including work from the Johns Hopkins Wilmer Eye Institute — and a portfolio of granted U.S. patents. Explore the clinical evidence and the technology that make IrisVision the original low-vision headset, not a copycat.
Peer-reviewed studies
Each study below is independent and links to the free full text. IrisVision is a low-vision aid that helps people use their remaining vision; it is not a cure or medical treatment.
-
Preliminary Evaluation of Two Digital Image Processing Strategies for Head-Mounted Magnification for Low Vision Patients
Wilmer Eye Institute, Johns Hopkins University School of Medicine; University of California, Berkeley
In an at-home clinical outcome study, IrisVision produced large, statistically significant improvements in reading ability (Cohen's d = 1.28) and visual-information tasks (d = 1.11), with participants rating the system 7.1 out of 10.
Read the full study Open access PMID 30834171
-
At-Home Trial of Four Different Head-Mounted Displays in Visual Rehabilitation of People with Stargardt Disease
Copenhagen University Hospital Rigshospitalet-Glostrup; University of Copenhagen
In people with Stargardt disease, IrisVision Live improved distance and near visual acuity and reading ability after home use.
Read the full study Open access PMID 38046087
-
Comparison of visual function analysis of people with low vision using three different models of augmented reality devices
Envision Research Institute; SUNY College of Optometry; Smith-Kettlewell Eye Research Institute
Across people with low vision, the majority of visual functions improved with IrisVision, including statistically significant gains in distance and near visual acuity and contrast sensitivity — outperforming a comparison device.
Read the full study Open access PMID 41060945
Listing a study here reflects that IrisVision was evaluated in that research; it does not imply endorsement by the authors or their institutions.
Patents
IrisVision's technology is protected by a portfolio of granted U.S. patents covering multi-modal vision enhancement, magnification, contrast-sensitivity compensation, and condition-specific processing.
- Multi-Modal Vision Enhancement System US 11,372,479 B2
- Methods and Systems for Generating a Magnification Region in Output Video Images US 11,144,119 B2
- Methods and Apparatus for Contrast Sensitivity Compensation US 11,475,547 B2
- Methods and Apparatus for Contrast Sensitivity Compensation US 10,963,999 B2
- Methods and Apparatuses for Compensating for Retinitis Pigmentosa US 11,546,527 B2
- Methods and Apparatus for Vision Enhancement US 10,444,833 B2
- Methods and Apparatus for Vision Enhancement US 10,146,304 B2
Patent-pending
Additional published applications extend the portfolio to remote vision testing, clinician management of head-mounted devices, and further vision-enhancement methods.
- Methods and Systems for Evaluating Vision Acuity and/or Conducting Visual Field Tests in a Head-Mounted Vision Device US 2022/0160223 A1 · Patent pending
- Method and System for Remote Clinician Management of Head-Mounted Vision Assist Devices US 2022/0171456 A1 · Patent pending
- Methods and Apparatus for Vision Enhancement US 2022/0043513 A1 · Patent pending